Ceryvyn Therapeutics Limited (CYVNY) AI Stock Analysis

• Market Cap: $10.86M
• Dividend Yield: N/A
• Average Volume (3M): 16.69K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.97
• Revenue Growth: -97.37%
• EPS Growth: N/A
• Country: US
• Employees: 33
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.16
• Shares Outstanding: 170,997,270
• 10 Day Avg. Volume: 38,139
• 30 Day Avg. Volume: 16,692
• PEG Ratio: >-0.01
• Price to Book (P/B): -2.00
• Price to Sales (P/S): 1215.83
• P/FCF Ratio: -0.94
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: >-0.01
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): $766.42K

• Rating: ― N/A
• Price Target: ―
• Action: N/A
• Date: ―

Ceryvyn Therapeutics Limited Business Overview & Revenue Model

Company Description

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endot...

Read more

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endot...

How the Company Makes Money

Opthea Limited generates revenue primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes potential income from licensing agreements, partnerships, and future sales of its therapies...

Read more

Opthea Limited generates revenue primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes potential income from licensing agreements, partnerships, and future sales of its therapies...

Ceryvyn Therapeutics Limited Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Ceryvyn Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYVNY, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 54.55 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYVNY.

Ceryvyn Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LXRX	55 Neutral	$996.70M	-14.89	-40.40%	―	-29.03%	54.11%
CRVS	53 Neutral	$1.21B	-22.48	-36.15%	―	―	8.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RGNX	46 Neutral	$590.16M	-2.36	-220.07%	―	12.00%	-9.21%
SLDB	43 Neutral	$1.10B	-5.37	-72.28%	―	―	31.81%
PRTA	41 Neutral	$504.13M	-11.83	-14.98%	―	427.32%	85.31%